Letter to the editor: Combination treatment with IL-1 antagonist, pentoxifylline and zinc for severe alcoholic hepatitis: Are we there yet?
- PMID: 35776003
- DOI: 10.1002/hep.32646
Letter to the editor: Combination treatment with IL-1 antagonist, pentoxifylline and zinc for severe alcoholic hepatitis: Are we there yet?
Comment on
-
IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.Hepatology. 2022 Oct;76(4):1058-1068. doi: 10.1002/hep.32478. Epub 2022 Jun 2. Hepatology. 2022. PMID: 35340032 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022 Mar 27. https://doi.org/10.1002/hep.32478. [Epub ahead of print]
-
- Park SH, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol. 2014;61(4):792-8.
-
- Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516-26.
-
- Fda C. Kineret®(anakinra) for injection, for subcutaneous use. [cited 2022 Apr 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
